Comparison · NCT02506959-083b6277
Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: Participants Who Experienced Grade 3 or Higher Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: Participants Who Experienced Grade 3 or Higher Adverse Events. Trial comparisons, record NCT02506959-083b6277. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02506959-083b6277
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.94 | 0.838 | 0.979 | wilson | |
| Risk in group 2 | 0.879 | 0.727 | 0.952 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0612 | -0.0644 | 0.218 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.925 | 1.24 | log | |
| Odds ratio, group 1 over group 2 | 2.16 | 0.451 | 10.4 | log | |
Number needed to treat, for one more participant with the outcome on Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel than on Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | 16.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.~Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant~Busulfan: Given IV~Gemcitabine Hydrochloride: Given IV~Melphalan: Given IV~Panobinostat: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant~Pharmacological Study: Correlative studies | 47 | 50 | OG000 |
| Group 2 | Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.~Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant~Busulfan: Given IV~Gemcitabine Hydrochloride: Given IV~Melphalan: Given IV~Panobinostat: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant~Pharmacological Study: Correlative studies | 29 | 33 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants Who Experienced Grade 3 or Higher Adverse Events
- Description
- Number of Participants who experienced grade 3 or higher Adverse Events during the first 100 days of the transplant.
- Time frame
- Up to day 100
- Population
Source ClinicalTrials.gov
Trial
- Title
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
- NCT number
- NCT02506959
- Phases
- PHASE2
- Conditions
- Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2025-03-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02506959?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02506959-083b6277